Interpretation of the Chinese guidelines for the diagnosis and management of patients with chronic coronary syndrome
-
摘要: 《中国慢性冠脉综合征患者诊断及管理指南》是我国首部针对慢性冠脉综合征(CCS)患者诊断及管理的指导性文件，全面介绍了CCS的定义、诊断流程、治疗策略以及长期管理，涵盖了CCS患者的全生命周期，包括合并症及特殊人群的最新管理建议。本解读旨在对《中国慢性冠脉综合征患者诊断及管理指南》进行详细解读，以帮助医疗专业人员更好地理解和应用该指南，指导临床实践，全面提升我国CCS患者管理水平。Abstract: As the first guiding document in China specifically tailored for the diagnosis and management of chronic coronary syndrome(CCS) patients, the Guidelines comprehensively introduce the definition, diagnostic process, treatment strategies, and long-term management of CCS, covering the full lifecycle of CCS patients, including the latest management recommendations for comorbidities and special populations. This interpretation aims to provide a detailed analysis of the Chinese Guidelines for Diagnosis and Management of Chronic Coronary Syndrome in Patients, facilitating medical professionals' better understanding and application of the Guidelines, guiding clinical practice, and comprehensively improving the management level of CCS patients in China.
-
Key words:
- chronic coronary syndrome /
- cardiovascular disease /
- diagnosis /
- management /
- treatment /
- antiplatelet drugs /
- special populations /
- guidelines
-
-
[1] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 慢性稳定性心绞痛诊断与治疗指南[J]. 中华心血管病杂志, 2007, 35(3): 195-206. https://www.cnki.com.cn/Article/CJFDTOTAL-WMIA201578050.htm
[2] 中华医学会心血管病学分会介入心脏病学组, 中华医学会心血管病学分会动脉粥样硬化与冠心病学组, 中国医师协会心血管内科医师分会血栓防治专业委员会, 等. 稳定性冠心病诊断与治疗指南[J]. 中华心血管病杂志, 2018, 46(9): 680-694. https://www.cnki.com.cn/Article/CJFDTOTAL-XXFZ201902001.htm
[3] Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J, 2020, 41(3): 407-477. doi: 10.1093/eurheartj/ehz425
[4] Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines[J]. J Am Coll Cardiol, 2023, 82(9): 833-955. doi: 10.1016/j.jacc.2023.04.003
[5] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国慢性冠脉综合征患者诊断及管理指南[J]. 中华心血管病杂志, 2024, 52(6): 13-38.
[6] Bhatt DL, Steg PG, Miller M, et al. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT[J]. J Am Coll Cardiol, 2019, 73(22): 2791-2802. doi: 10.1016/j.jacc.2019.02.032
[7] Samuel M, Tardif JC, Khairy P, et al. Cost-effectiveness oflow-dose colchicine after myocardial infarction in the colchicine cardiovascular outcomes trial(COLCOT)[J]. Eur Heart J Qual Care Clin Outcomes, 2021, 7(5): 486-495.
[8] Nidorf SM, Fiolet A, Mosterd A, et al. Colchicine in patients with chronic coronary disease[J]. N Engl J Med, 2020, 383(19): 1838-1847.
-
计量
- 文章访问数: 481
- 施引文献: 0
下载: